What is Vertex Pharmaceuticals Incorporated's stock symbol?
Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "VRTX."
Where is Vertex Pharmaceuticals Incorporated's stock going? Where will Vertex Pharmaceuticals Incorporated's stock price be in 2017?
25 equities research analysts have issued 1 year target prices for Vertex Pharmaceuticals Incorporated's shares. Their forecasts range from $75.00 to $139.00. On average, they anticipate Vertex Pharmaceuticals Incorporated's share price to reach $102.28 in the next year.
When will Vertex Pharmaceuticals Incorporated announce their earnings?
Vertex Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.
What are analysts saying about Vertex Pharmaceuticals Incorporated stock?
Here are some recent quotes from research analysts about Vertex Pharmaceuticals Incorporated stock:
Cowen and Company analysts commented, "Last week we hosted meetings with Vertex management in Chicago." (2/11/2017)
Maxim Group analysts commented, "The global launch of Orkambi in the homozygote CF population continues to make progress, and growth is expected as more European countries come online. However, as we move through 2017, our attention is turning towards expected data in the heterozygote population, where we believe Vertex must be successful to drive long-term value." (2/3/2017)
According to Zacks Investment Research, "Vertex reported better-than-expected fourth-quarter 2016 results. Vertex has two cystic fibrosis (CF) drugs in its portfolio with blockbuster potential – Kalydeco & Orkambi. Its efforts to get the drugs approved for additional indications are encouraging. Label expansion will increase the patient population and boost sales. Vertex’s CF pipeline is also strong. However, we believe the 2017 Orkambi revenue guidance is below expectations and dependent on reimbursement discussions in Europe. Vertex expects that the upper end of the Orkambi sales guidance will be met only if it gets additional reimbursement and approvals in different European markets. Moreover, Vertex’s shares have consistently underperformed the Zacks categorized Biomed/Genetics industry in the past one year. Investor focus will now be on the triple combination CF regimens which are crucial for long-term growth at Vertex." (1/31/2017)
Needham & Company LLC analysts commented, "Vertex announced preliminary 2016 financial results and issued initial 2017 guidance last week. Total 2016 CF product revenues were $1.68B, in line with our $1.68B est. The company is scheduled to announce 2016 financial results 1/25/17. Guidance ($1.1-1.3B Orkambi and $690-700M Kalydeco) appears conservative, w/ mgmt. assuming flat Kalydeco sales and minimal Orkambi revenue growth next yr. Our new Orkambi and Kalydeco estimates are $1.41B (was $1.57B) and $716.0M (was $749.0M). Key milestones in 2017 include top-line results from Phase 3 trials of IVA/TEZ in 1H17 and initial Phase 2 triple combination (IVA/TEZ/VX-440 and IVA/TEZ/VX-152) data in 2H17." (1/20/2017)
HC Wainwright analysts commented, "Rare Find"The brokerage listed following four key factors to reach its conclusion on the stock:No change in underwhelming view on Orkambi.The 661/Kalydeco double is also not likely to perform better than Orkambi .Ongoing final stage program of 661 is not likely to yield any commercial upside.The expected triple combo continued to be far way.Even if triple combo is successful, it could only be a replacement and not complement Orkambi.The previous M&A thesis is at its lowest point of any likelihood.In a research note, the analysts stated, "We have all seen VRTX once before lose everything in the HCV space, in our view, due to failure to adapt to change and stay competitive. While we are not saying that a collapse of similar proportions is likely in CF, we nonetheless suspect that VRTX is no longer well positioned to remain the leader of the pack in the future." (10/24/2016)
Who owns Vertex Pharmaceuticals Incorporated stock?
Vertex Pharmaceuticals Incorporated's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (8.09%), State Street Corp (4.74%), Orbimed Advisors LLC (0.87%), Franklin Resources Inc. (0.58%), Fred Alger Management Inc. (0.55%) and Two Sigma Investments LP (0.41%). Company insiders that own Vertex Pharmaceuticals Incorporated stock include Amit Sachdev, David Altshuler, Elaine Ullian, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Margaret G Mcglynn, Paul M Silva, Stuart A Arbuckle, Terrence C Kearney and Yuchun Lee.
Who sold Vertex Pharmaceuticals Incorporated stock? Who is selling Vertex Pharmaceuticals Incorporated stock?
Vertex Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Fred Alger Management Inc., Thrivent Financial for Lutherans, Janus Capital Management LLC, GLG LLC, Employees Retirement System of Texas, NN Investment Partners Holdings N.V. and New York State Teachers Retirement System. Company insiders that have sold Vertex Pharmaceuticals Incorporated stock in the last year include Amit Sachdev, Ian F Smith, Joshua S Boger, Paul M Silva and Stuart A Arbuckle.
Who bought Vertex Pharmaceuticals Incorporated stock? Who is buying Vertex Pharmaceuticals Incorporated stock?
Vertex Pharmaceuticals Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Orbimed Advisors LLC, Baillie Gifford & Co., Asset Management One Co. Ltd., State Street Corp, AMF Pensionsforsakring AB, AQR Capital Management LLC and FIL Ltd.
How do I buy Vertex Pharmaceuticals Incorporated stock?
Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Vertex Pharmaceuticals Incorporated stock cost?
One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $88.33.